StockNews.com lowered shares of Tactile Systems Technology (NASDAQ:TCMD – Free Report) from a strong-buy rating to a buy rating in a research note released on Monday morning.
Several other equities analysts also recently commented on the stock. B. Riley began coverage on shares of Tactile Systems Technology in a report on Thursday, September 26th. They issued a “buy” rating and a $23.00 target price on the stock. Oppenheimer downgraded shares of Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. Finally, BTIG Research downgraded shares of Tactile Systems Technology from a “buy” rating to a “neutral” rating in a report on Tuesday, November 5th.
View Our Latest Analysis on Tactile Systems Technology
Tactile Systems Technology Price Performance
Institutional Investors Weigh In On Tactile Systems Technology
Large investors have recently bought and sold shares of the business. Arcadia Investment Management Corp MI bought a new stake in Tactile Systems Technology in the third quarter worth $29,000. Gladius Capital Management LP bought a new stake in Tactile Systems Technology in the third quarter worth $44,000. Quarry LP bought a new stake in Tactile Systems Technology in the second quarter worth $46,000. Magnetar Financial LLC bought a new position in Tactile Systems Technology during the second quarter valued at $130,000. Finally, SG Americas Securities LLC bought a new position in Tactile Systems Technology during the third quarter valued at $156,000. Institutional investors own 83.43% of the company’s stock.
About Tactile Systems Technology
Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.
See Also
- Five stocks we like better than Tactile Systems Technology
- Are Penny Stocks a Good Fit for Your Portfolio?
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Why is the Ex-Dividend Date Significant to Investors?
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- ESG Stocks, What Investors Should Know
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.